Search

Your search for "GNPX" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy

August 16, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that the United States Patent and Trademark Office (“USPTO”) has granted Genprex U.S. Patent No: 11,278,592 B2. According to the update, the patent covers methods of using REQORSA(TM) Immunogene Therapy in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose

August 15, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that the Safety Review Committee (“SRC”) has approved continuation of the Acclaim-1 phase 1/2 clinical trial of REQORSA(TM) in combination with Tagrisso(R) (osimertinib) to treat late-stage non-small cell lung cancer (“NSCLC”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

July 13, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its manufacturing leadership will present sessions on cutting-edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit. The event is taking place from July 19-21, 2022, in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences

June 2, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting at two upcoming investor conferences: the LD Micro Invitational and the BIO International Convention. The company’s participation will focus on its gene therapies for cancer and diabetes. Slated for June 7–9, 2022, the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference

May 19, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its CEO and President Rodney Varner will be providing a virtual overview of Genprex’s pioneering gene therapies to investors at the H.C. Wainwright Global Investment Conference. The event is slated […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist

May 9, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced that chief medical officer Mark Berger, MD, will be participating the upcoming Cancer Progress Conference. The conference, which will be held virtually, is slated for May 10–12, 2022. Berger has been invited to participate […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update

May 5, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has issued a shareholder letter and corporate update outlining the company’s recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond. “We have had a strong […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences

April 18, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, and management will be involved in two upcoming conferences. GNPX presenters will include chief financial officer Ryan Confer and chief medical officer Mark Berger. The conference presentations will spotlight the company’s gene therapies for cancer and […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment

March 31, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced the opening for patient enrollment of its Acclaim-2 clinical trial. According to the update, Acclaim-2 is an open-label, multi-center phase 1/2 clinical trial evaluating the company’s lead drug candidate, REQORSA(TM) Immunogene Therapy, in combination […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference

March 23, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will provide an overview of the company’s gene therapies for cancer and diabetes at the 2022 BIO Europe Spring Investor Conference. The event is scheduled to take […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial

March 2, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the first patient was dosed in the Acclaim-1 clinical trial. The open-label, multi-center phase 1/2 clinical trial will evaluate the company’s lead drug candidate, REQORSA(TM) Immunogene Therapy, in combination with Tagrisso(R) (osimertinib) in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences

February 9, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two investor conferences this month. The company has announced that president and CEO Rodney Varner will be presenting to investors at both the 2022 BIO CEO and Investor Conference and at the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System

January 27, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators published positive preclinical data for the use of Genprex’s ONCOPREX(R) Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic colorectal cancer. The preclinical study, published in the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites

January 10, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial. The trial combines the company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid) Immunogene Therapy with AstraZeneca’s Tagrisso(R) as a potential […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Conferences

January 5, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two January conferences. The company announced that president and CEO Rodney Varner and chief medical officer Mark Berger, MD, will lead presentations in both the HC Wainwright 2022 Bioconnect Conference and the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Oncology R&D Pipeline to Include Small Cell Lung Cancer

January 4, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has expanded its oncology research and development pipeline to include small cell lung cancer (“SCLC”) as an additional disease indication for its lead drug candidate, REQORSA(TM) Immunogene Therapy. SCLC represents approximately 10-15% […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted Fast Track Designation for Proprietary Immunogene Therapy from FDA

January 3, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it has received fast track designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate: REQORSA(TM) Immunogene Therapy. The designation is for REQORSA in combination with Merck & Co’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar

November 16, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the company’s president and chief executive officer Rodney Varner will be showcasing the company’s novel gene therapies in cancer and diabetes to investors via a webinar with CEO Roadshow. The CEO Roadshow webinar […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference

September 29, 2021

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments

September 28, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of chief medical officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences

September 20, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, will be a featured presenter in both the CEO Roadshow Webinar series and the Benzinga Healthcare Small Cap Conference.Genprex president and CEO Rodney Varner will be presenting at both events, with the presentations focused on the company’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in CEO Roadshow Webinar Series

July 20, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will be participating in a webinar series with CEO Roadshow. The CEO Roadshow features small- and mid-cap stocks on the verge of a breakout or having other […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Achieves Key Milestones for Its Acclaim-1 Clinical Trial

June 23, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed and confirmed all comments have been addressed regarding the company’s protocol for the Acclaim-1 clinical trial. The open-label, multi-center Phase 1/2 clinical trial will […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present in Noble Capital Markets’ Virtual Roadshow

May 19, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in Noble Capital Markets’ Virtual Roadshow Series, presented by Channelchek on May 20, 2021. The virtual roadshow will feature a corporate presentation from Genprex’s president and CEO Rodney Varner followed […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

May 10, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

May 6, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

May 5, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

May 4, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

April 21, 2021

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

April 20, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

April 12, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

April 5, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

March 30, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference

March 24, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences

March 1, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering

February 9, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day

February 4, 2021

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it joins with millions of healthcare advocates around the world in support of World Cancer Day. The designation seeks to raise awareness, elevate public understanding of the global cancer burden, promote greater equity and ensure that cancer control […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update

February 1, 2021

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

January 27, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

January 21, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).